What Beta Bionics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 18 | 47 |
| Total trades | 20 | 64 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 1,126 | 156,898 |
| Disposed | 125,846 | 218,780 |
| Net activity | −124,720 | −61,882 |
Common stock only — 1 reported trade in the last 12 months is in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Feider Stephen | Chief Financial Officer | Nov 09 | Open-market sale · S | −744 | $17.00 | −$12.6K | 159,378 |
| Feider Stephen | Chief Financial Officer | Nov 09 | Exercise / conversion · M | +744 | $5.10 | +$3.79K | 160,122 |
| Feider Stephen | Chief Financial Officer | Nov 05 | Open-market sale · S | −382 | $17.04 | −$6.51K | 159,378 |
| Feider Stephen | Chief Financial Officer | Nov 05 | Exercise / conversion · M | +382 | $5.10 | +$1.95K | 159,760 |
| Hopman Mark | Chief Commercial Officer | Nov 02 | Open-market sale · S | −370 | $16.90 | −$6.25K | 54,143 |
| Mensinger Mike | Chief Product Officer | Oct 27 | Open-market sale · S | −2,650 | $22.00 | −$58.3K | 174,740 |
| Hopman Mark | Chief Commercial Officer | Oct 26 | Open-market sale · S | −821 | $20.00 | −$16.4K | 54,513 |
| Hopman Mark | Chief Commercial Officer | Oct 14 | Open-market sale · S | −775 | $17.35 | −$13.4K | 55,334 |
| Hopman Mark | Chief Commercial Officer | Oct 01 | Open-market sale · S | −370 | $18.96 | −$7.02K | 56,109 |
| Jones Christy | Director | Sep 22 | Open-market sale · S | −6,430 | $23.00 | −$148K | 19,564 |
| Mensinger Mike | Chief Product Officer | Sep 16 | Open-market sale · S | −2,650 | $22.00 | −$58.3K | 177,390 |
| Hopman Mark | Chief Commercial Officer | Sep 16 | Open-market sale · S | −30,779 | $20.13 | −$620K | 56,479 |
| Hopman Mark | Chief Commercial Officer | Sep 14 | Open-market sale · S | −775 | $15.52 | −$12K | 86,382 |
| Hopman Mark | Chief Commercial Officer | Sep 09 | Disclosed 10b5-1 sale · S | −35,994 | $18.46 | −$665K | 88,033 |
| Saint Sean | President & CEO | Sep 03 | Open-market sale · S | −5,641 | $20.08 | −$113K | 398,429 |
| Saint Sean | President & CEO | Sep 02 | Open-market sale · S | −16,867 | $19.11 | −$322K | 404,070 |
| Feider Stephen | Chief Financial Officer | Sep 02 | Open-market sale · S | −6,675 | $19.11 | −$128K | 159,378 |
| Mensinger Mike | Chief Product Officer | Sep 02 | Open-market sale · S | −4,375 | $19.11 | −$83.6K | 180,040 |
| Russell Steven Jon | Chief Medical Officer | Sep 02 | Open-market sale · S | −4,221 | $19.11 | −$80.7K | 169,628 |
| Hopman Mark | Chief Commercial Officer | Sep 02 | Open-market sale · S | −5,327 | $19.11 | −$102K | 124,027 |
Loading...